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Epoxide-Mediated Differential Packaging of Cif and Other Virulence
Factors into Outer Membrane Vesicles
Alicia E. Ballok, Laura M. Filkins, Jennifer M. Bomberger, Bruce A. Stanton, George A. O’Toole
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA
Pseudomonas aeruginosa produces outer membrane vesicles (OMVs) that contain a number of secreted bacterial proteins, in-
cluding phospholipases, alkaline phosphatase, and the CFTR inhibitory factor (Cif). Previously, Cif, an epoxide hydrolase, was
shown to be regulated at the transcriptional level by epoxides, which serve as ligands of the repressor, CifR. Here, we tested
whether epoxides have an effect on Cif levels in OMVs. We showed that growth of P. aeruginosa in the presence of specific epox-
ides but not a hydrolysis product increased Cif packaging into OMVs in a CifR-independent fashion. The outer membrane pro-
tein, OprF, was also increased under these conditions, but alkaline phosphatase activity was not significantly altered. Addition-
ally, we demonstrated that OMV shape and density were affected by epoxide treatment, with two distinct vesicle fractions
present when cells were treated with epibromohydrin (EBH), a model epoxide. Vesicles isolated from the two density fractions
exhibited different protein profiles inWestern blotting and silver staining. We have shown that a variety of clinically or host-
relevant treatments, including antibiotics, also alter the proteins packaged in OMVs. Proteomic analysis of purified OMVs fol-
lowed by an analysis of transposonmutant OMVs yielded mutants with altered vesicle packaging. Finally, epithelial cell cytotox-
icity was reduced in the vesicles formed in the presence of EBH, suggesting that this epoxide alters the function of the OMVs.
Our data support a model whereby clinically or host-relevant signals mediate differential packaging of virulence factors in
OMVs, which results in functional consequences for host-pathogen interactions.
Pseudomonas aeruginosa is an opportunistic pathogen that em-ploys multiple mechanisms of virulence factor delivery. These
mechanisms include secretion into themilieu via numerous secre-
tion systems (1) and direct injection into the host by way of the
type III secretion system (2). A third mechanism, virulence factor
delivery via outer membrane vesicles (OMVs) (3), was identified
late last century, yet the significance of this delivery mechanism
has only recently been recognized.
Production of OMVs appears to be a conserved physiological
trait among Gram-negative bacteria (4). These versatile vesicles
have been shown to contribute to biofilm formation, bacterial
defense against toxic compounds, horizontal gene transfer, patho-
genic and nonpathogenic interactions, and other bacterial pro-
cesses (5–10). While bacteria seem to produce vesicles as part of
normal growth (11), they also hypervesiculate in response to stres-
sors such as antibiotics, toxic compounds, andmembrane pertur-
bations (12–14). Hypervesiculation may serve as an important
mechanism of stress tolerance under some conditions (15). It is
still not clear whether vesicle formation and packaging of cellular
proteins constitute a directed or stochastic process (4).
OMV production is better characterized in P. aeruginosa than
in many other species. Vesicle formation in this species has been
attributed to specific forms of negatively charged lipopolysaccha-
ride (LPS) (16), the membrane-intercalating quorum-sensing
molecule Pseudomonas quinolone signal (PQS) and its interaction
with lipid A (17, 18), and loss of peptidoglycan anchoring by outer
membrane proteins (19). Previous work has shown that P. aerugi-
nosa OMVs are damaging to epithelia, being both inflammatory
and cytotoxic (6, 20). Additionally, bacterial factors important for
virulence, such as LPS, phospholipases, proteases, hemolysin, al-
kaline phosphatases, and the CFTR inhibitory factor, Cif (16, 21),
have been identified in OMVs. Furthermore, these vesicles can
fuse directly with the eukaryotic membrane to deliver their con-
tents to the host cell cytoplasm (6).
The Cif protein was discovered based on its ability to alter
trafficking of CFTR, a mammalian ABC transporter whose loss of
function results in the disease cystic fibrosis (CF) (22). Cif, an
epoxide hydrolase enzyme, alters the recycling of CFTR to the
apical membrane and instead targets CFTR for degradation, al-
though the precise mechanism by which this bacterial protein ex-
erts its effect has not yet been determined (23). In addition to
effects on CFTR, Cif induces the degradation of transporter asso-
ciated with antigen processing 1 (TAP1), which reduces major
histocompatibility complex (MHC) class I antigen presentation
(24).
Previously,wehave shownthatproductionofCifbyP. aeruginosa
is regulated directly by a TetR-family regulator, CifR (25). The
CifR protein binds to two locations in the cif promoter to repress
transcription (26). In the presence of specific epoxide inducers,
CifR presumably binds to these ligands and releases repression of
cif gene expression. Deletion of this epoxide-responsive regulator
dramatically increases cif gene expression by200-fold (26).
Epoxides, while potentially toxic, are produced as a by-product
of metabolism in eukaryotes and play key roles in mammalian
signaling. For example, epoxide-containing fatty acids are impor-
tant anti-inflammatory molecules in mammals that inhibit
NF-B activation and also promote tissue regeneration (27, 28).
Furthermore, human-derived epoxides are produced by cells such
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as leukocytes in the lung (29), a common site of P. aeruginosa
infections (30).
In this study, we aimed to explore whether epoxides affect
packaging of Cif and other proteins into OMVs. The data pre-
sented here support our hypothesis that P. aeruginosa OMV pro-
duction is altered by the presence of epoxides and likely other
extracellular signals, lending support to the concept of selective
packaging of OMV cargo. Furthermore, we propose that that
modulation of OMV cargo has functional consequences for host-
pathogen interactions and thus may represent an underappreci-
ated target for antimicrobial interventions.
MATERIALS AND METHODS
Strains. Experiments were performed with P. aeruginosa UCBPP-PA14
(31), abbreviated here as P. aeruginosa PA14, the cif and cifR gene deletion
mutants (21, 25), and transposon mutants from the nonredundant P.
aeruginosa PA14 transposon mutant library developed by Ausubel and
colleagues (32).
OMVpurification.Vesicles were purified as described previouslywith
some modifications (20). Briefly, flasks containing lysogeny broth (LB)
medium were inoculated at 1:1,000 with overnight cultures of P. aerugi-
nosa PA14 and grown with shaking (200 RPM) at 37°C for 12 h. A 1 mM
concentration of epibromohydrin (EBH), styrene oxide, epoxyhexane,
glycidol, or 3-bromo-1,2-propanediol was added, as appropriate. Cells
were pelleted by centrifugation, and supernatants were passed through a
0.45-mfilter. To isolate OMVs, filtered supernatants were concentrated
with a 100,000-molecular-weight-cutoff (MWCO) filter (Amicon) and
then centrifuged for 1.5 h at 39,000  g to pellet vesicles. Supernatants
were removed, and the vesicle pellet was resuspended by pipetting after
approximately 30 min of incubation either in phosphate-buffered saline
(PBS), followed by use inWestern blotting and enzyme assays since addi-
tional purification was not required for these assays, or in 50 mMHEPES
buffer (pH 6.8), which loosened the OMV pellet, and layered in an Op-
tiprep (iodixanol) gradient (Sigma) (20) for further purification. OMVs
layered on the Optiprep gradient were centrifuged for 16 to 20 h at
100,000 g, and fractions containing vesicles based on previous analysis
(20) were removed. Vesicles were washed several times in PBS using a
10,000-MWCO filter (Amicon) to remove Optiprep solution.
Cell fractionation. Vesicle-free supernatants were collected after fol-
lowing the OMV concentration protocol (as described above), and these
supernatants were concentrated with a 10,000-MCWO filter. Periplasmic
and spheroplast sample preparation was based on methods of Jensch and
Fricke (33). Periplasmic fractions were obtained by resuspending pelleted
P. aeruginosa in a solution containing 50 mMTris HCl (pH 8.0), 200 mM
MgCl2, 5 mg/ml lysozyme, and protease inhibitor (Roche) for 30 min at
room temperature. Spheroplasts were separated from the periplasmic
contents by centrifugation at 11,000 g for 10 min, and then the sphero-
plasts, consisting of the inner membrane and cytoplasm, were resus-
pended in 10 mM Tris HCl (pH 7.5) plus 50 mM MgCl2 and lysed by
sonication.
Protein quantitation. Protein content of the vesicle and cell fractions
were determined using the Pierce bicinchoninic acid (BCA) protein assay
kit (Thermo Scientific), using bovine serum albumin (BSA) as a standard
and following the manufacturer’s instructions.
MUP assay. 4-Methylumbelliferyl phosphate (MUP) was used to
quantify alkaline phosphatase activity, based on methods described pre-
viously (34). Briefly, 20g of PBS-resuspended vesicles were added to 100
mM Tris-HCl (pH 7.5) and 1 MMUP and then incubated at 37°C with
periodic shaking. Fluorescence was measured on a Spectramax plate
reader (Molecular Devices) at 390-nm excitation and 460-nm emission.
NPPC assay. Phospholipase activity was measured using the p-nitro-
phenylphosphorylcholine (NPPC) colorimetric assay (35). Briefly, vesi-
cles in PBS were normalized to 20 g protein, or alternatively, 12-h cul-
ture supernatants were used as a source of OMVs, as needed for each
experiment. OMVs were added to a solution containing 2mMNPPC and
60%(wt/vol) sorbitol in 100mMTris-HCl (pH7.5) in a 96-well plate. The
plate was incubated at 37°C with periodic shaking, and absorbance was
measured (410 nm) in a Spectramax plate reader. Where appropriate,
vesicles were permeabilized with chloroform and SDS.
Protein detection. For detection of proteins from OMVs and cellular
fractions, 50 g total protein was added per well, unless otherwise stated,
and electrophoresed on a 4 to 15% or 12% SDS-PAGE gel (Bio-Rad). Cif,
OprF, and SadBwere detected byWestern blotting as described previously
(20, 26, 36). Silver staining was performed using the Silver Quest kit
(Novex) according to the manufacturer’s instructions.
Proteomics. OMVs were isolated for proteomic analysis from three
preparations of OMVs from P. aeruginosa PA14 and from preparations of
OMVs obtained from two clinical isolates using a previously published
protocol (6). In brief, LB was inoculated with P. aeruginosa PA14 from a
glycerol stock and incubated at 37°C using rotation until the bacterial
count reached an optical density at 600 nm of 1.5, corresponding to a
bacterial count of 5 109 CFU/ml (16 to 18 h of culture). Bacteria were
harvested by centrifuging cultures at 4,800 g for 30 min at 4°C. Filtered
supernatant was then concentrated with a 30-kDa cutoff filter, andOMVs
were pelleted and placed in an Optiprep gradient. Gradients were centri-
fuged at 100,000 g for 16 h at 4°C. After ultracentrifugation,OMVswere
removed from the gradient and proteins were precipitated using trichlo-
roacetic acid precipitation. Precipitated proteins were resuspended in
Laemmli sample buffer containing 200 mM dithiothreitol and heated for
5min at 85°C. Samples were then separated using SDS-PAGE and stained
with colloidal Coomassie stain (Invitrogen). After overnight destaining in
water, gel lanes were divided into 4 sections, excised, and analyzed for
protein content using microcapillary liquid chromatography-tandem
mass spectrometry (LC/MS/MS) at the TaplinMass Spectrometry Facility
at Harvard University.
For identification of proteins in untreated and EBH-treated fractions,
lysed OMV samples were separated by SDS-PAGE in a 4 to 15% gel and
silver stained. Bands were excised and destained before trypsin digestion.
Samples were analyzed by LC-MS/MS on a linear ion trap (LTQ) mass
spectrometer. Five microliters of the material was loaded onto a 100-m
by 120-mm capillary column packed with Magic C18 (5-m particle size,
20-nm pore size, Michrom Bioresources, California) at a flow rate of 500
nl/min. Peptides were separated by a gradient of 5 to 40% CH3CN–0.1%
formic acid over 30 min, 40 to 100% CH3CN–0.1% formic acid over 6
min, and 100% CH3CN for 2 min. Product ion spectra were searched
using the SEQUEST search engine on Bioworks Browser Rev 3.3.1 SP1
(ThermoFisher Scientific,Massachusetts) against aP. aeruginosadatabase
with sequences in forward and reverse orientations. The database was
indexed to allow for full trypsin enzymatic activity, two missed cleavages,
and peptides between the molecular masses of 350 and 5,000 kDa. Search
parameters set themass tolerance at 2Da for precursor ions and 0.8Da for
fragment ions. Cross-correlation (Xcorr) significance filters were applied
to limit the false-positive rates to less than 1% in both data sets. The Xcorr
values were as follows: (1), 1.5; (2), 2.0; (3), 2.5; (4), 3.0. Other
filters applied were a minimum peptide cutoff of 2, as well as a DeltaCN
value (the difference between normalized Xcorr functions) of0.1. Mass
spectroscopic analysis of trypsin-digested proteins was performed at the
Vermont Genetics Network Proteomics Facility at the University of Ver-
mont.
TEM of OMVs. Purified vesicles in PBS were spotted onto Formvar
grids (ElectronMicroscopy Sciences) and negatively stained with 1% am-
monium molybdate (pH 7.0). Transmission electron microscopy (TEM)
images were obtained at the Rippell Electron Microscopy facility at Dart-
mouth College, at 100 kV, on a FEI Tecnai F20ST field emission gun
(FEG) instrument, equipped with a digital camera (XR-41B; Advanced
Microscopy Techniques). Eight images were obtained for each condition,
randomized, numbered, and given to a third party for vesicle measure-
ment. Vesicle area was quantified as number of pixels per vesicle (ImageJ
software).
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ELISA and cytotoxicity assays. CFBE41o cells (F508/F508), de-
rived from a CF patient, were grown to confluence in 24-well plates as
described previously (54). Purified OMVs from wild-type (WT) cultures
grownwith or without 1mMEBHwere added towashed epithelial cells as
described previously (6) and incubated for 12 to 24 h at 37°C with 5%
CO2. After incubation, cell culturemediumwas removed and centrifuged
at 13,000  g for 3 min to remove debris. The cytokines interleukin 6
(IL-6), IL-8, Gro	, and Gro
 were measured in the supernatants by en-
zyme-linked immunosorbent assay (ELISA) (Promokine), and cytotoxic-
ity was assessed by measuring lactate dehydrogenase (LDH) release using
the Cyto Tox 96 nonradioactive cytotoxicity assay (Promega) per the
manufacturer’s instructions.
Membrane lipid quantification. Vesicle lipids were quantified using
FM 4-64 (Invitrogen) as described previously (11). Briefly, vesicles from
equivalent volumes of triplicate cultures were incubated with fluorescent
dye at a final concentration of 3.3 g/ml in PBS for 20 min at 37°C, and
fluorescence was measured at an excitation wavelength of 506 nm and an
emission wavelength of 750 nm.
Growth assay. Overnight cultures of P. aeruginosa were subcultured
(1:100) into culture tubes containing 1 mM epoxide in 5 ml LB. Cultures
were grown at 37°C, and optical density was measured at 600 nm every 30
min for 3.5 h.
Electrophoretic mobility shift assay. Electrophoretic mobility shift
assays (EMSA) were performed as described previously (25), with the
following specifications: purified CifR (160 fmol) was coincubated with
20 fmol of a 5= biotinylated oligonucleotide (5=CCTCCATTATTTGTAT
CGATCACTATAAATTTACTT [26]) for 30 min at room temperature in
a volume of 10 l. EBH, epoxyhexane, or glycidol (1 mM) was added as
needed.
cDNA synthesis and qRT-PCR. cDNA was synthesized from 1 g
total RNA isolated from P. aeruginosa PA14 using the QuantiTect reverse
transcription kit (Qiagen), following prescribed protocols. Quantitative
reverse transcription-PCR (qRT-PCR) was performed using cDNA,
primers designed for the plcN, katA, sodM, lexA, algD and rplU genes (see
Table S1 in the supplementalmaterial), a transcriptional control (37), and
Maxima SYBR green qPCR master mix (Fermentas). A Bio-Rad iCycler
instrument was used to carry out the reactions, and data analysis was
performed using CFXmanager software (Bio-Rad). Data are expressed as
picograms input cDNA of gene of interest relative to the rplU gene tran-
script control.
RESULTS
Epoxides affect Cif packaging in a CifR-independent fashion.
We have previously shown that Cif is packaged into OMVs (21)
and that epoxides such as epibromohydrin (EBH) induce expres-
sion of Cif through derepression of CifR, a transcriptional regula-
tor (25). We questioned whether epoxides also impacted the
amount of the Cif protein packaged into these vesicles. To this
end, we grew wild-type P. aeruginosa PA14 and the cifRmutant
in the presence and absence of 1mMEBH, as described previously
(21, 25, 26).We showed previously that this concentration of EBH
did not alter the growth of P. aeruginosa compared to results with
the vehicle control (dimethyl sulfoxide [DMSO]) (26). Cultures
were fractionated into supernatant, OMV, periplasmic, and
spheroplast fractions (Fig. 1A), concentrated such that 50g total
protein is loaded per well, and the Cif protein was detected by
Western blotting. SadB, a protein previously shown to be cyto-
plasmically localized (21), served as a control to demonstrate a
lack of cytoplasmic contamination from the spheroplast fraction
or from the periplasmic fraction (see Fig. S1A in the supplemental
material).
Low levels of Cif were noted in all of the fractions from thewild
type grown in the absence of EBH, and the level of the Cif protein
was increased in all fractions isolated from cells grown in the pres-
ence of EBH. As expected, the cifR deletion mutant had much
more Cif in the spheroplast and periplasmic fractions due to loss
of CifR-mediated repression, but surprisingly, there was relatively
little Cif in the OMV and supernatant fractions given the large
amount of Cif produced in the cell-associated fractions. However,
in the presence of EBH, a large quantity of the Cif protein was
observed in the supernatant and OMV fractions (Fig. 1A). These
data suggest that EBH increased Cif packaging into OMVs, and
perhaps secretion of the protein, and did so in aCifR-independent
manner.
OprF increases in EBH-treated vesicles. OprF is an outer
membrane porin previously shown to be important for virulence
in an animal model (38), and loss of the corresponding gene was
recently shown to increase vesiculation in P. aeruginosa (19).
Thus, we decided to test whether packaging of this protein into
OMVs is affected by the addition of epoxide. In the presence of
epoxide, the amount of OprF produced did not change in the
periplasmic and spheroplast fractions but did increase to a similar
extent for both theWT and thecifRmutant in theOMV fraction
(Fig. 1B).
The increased OprF and Cif in EBH-treated OMVs suggested
that there may be an interrelationship between these two proteins
in regard to vesicle packaging. We tested whether mutations of
either protein affected packaging of the other. Wild-type and cif
mutant vesicles purified from cultures grown with and without
EBH had similar levels of the OprF protein (see Fig. S1B in the
supplemental material). Similarly, OMV levels of the Cif protein
remained unchanged in an oprF transposon mutant (see Fig.
FIG 1 Cif andOprF levels change in response to epoxides. (A)Western blot of
fractions of cultures grown overnight in the presence and absence of 1 mM
epibromohydrin (EBH), a model epoxide. The cifR deletion strain shows in-
creased levels of the Cif protein in the spheroplast and periplasmic fractions
due to loss of CifR-mediated repression, as reported elsewhere (26). Note the
increase in the Cif protein in the supernatant and OMV fractions for cells
grown in the presence of EBH. (B)Western blot of the same samples as in panel
A, probed with an OprF antibody. Note that OprF is present in the vesicle
fractions and increases in those samples with EBH.
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S1C). These data indicate that while Cif andOprF proteins appear
to show similar responses to EBH treatment, they are not depen-
dent on one another for this effect.
Other epoxides alter proteins in vesicles. Previously, we had
shown that there was some specificity in epoxide inducers of cif
gene expression (26). It follows that there may be some specificity
with regard to epoxides that induceOMVprotein changes. To test
this idea, we purified OMVs from the cifR deletion strain grown
with three epoxides shown to have various effects on Cif protein
expression in whole cells (26): styrene oxide (a strong inducer),
epoxyhexane and glycidol (both weaker inducers), and the vicinal
diol, hydrolysis product of EBH, which does not alter cif gene
expression (26).
Styrene oxide (SO) had a strong stimulatory effect on Cif pro-
tein abundance in vesicles, although slightly less than the effect
noted for EBH (Fig. 2). Epoxyhexane (EH) and glycidol (Gly) also
increased vesicle packaging in a cifR deletion mutant, although to
levels far lower than those with EBH (Fig. 2). The vicinal diol of
EBH, 3-bromo,1,2-propandiol (3Br), did not dramatically in-
crease packaging of Cif into the OMVs, showing that it is the
epoxide rather than its hydrolysis product that induces the re-
sponse. A growth curve revealed that none of these compounds
altered the growth rate in liquid culture (see Fig. S2A in the sup-
plemental material).
As mentioned above, the epoxides EH and Gly tested above
could weakly induce expression of the cif gene (26). This weak
induction could be due to the fact that these compounds may be
poor ligands for CifR binding. Thus, we tested whether these
weaker inducers could reduce CifR binding to DNA in vitro, as
shown previously for EBH (25, 26). As determined using EMSA,
both glycidol and epoxyhexane do have a minimal effect on CifR-
DNA binding, although much less than that with EBH (see Fig.
S2B in the supplemental material). These data would support the
notion that, as predicted, these small hydrophobic epoxides likely
diffuse into the cell but have a small effect onCif expression due to
their limited ability to act as a CifR ligand.
Taken together, these data show that there is specificity in the
epoxides that can mediate changes in OMV protein packaging,
with EBH and SO having a strong impact on altering OMV pack-
aging of Cif and the related epoxides EH and Gly having little
impact on packaging of Cif.
Epoxide addition reduces phospholipase packaging but does
not alter alkaline phosphatase packaging in OMV. Since we had
already observed that epoxide treatment alters packaging into
OMVs of the OprF and Cif proteins, we decided to test whether
other well-documented, OMV-associated proteins are impacted
by the addition of EBH (6). We tested the alkaline phosphatase
activities of vesicles produced with and without EBH and found
no significant difference (Fig. 3).
Next, we assessed the phospholipase activity of these OMVs
and found a dramatic reduction in activity upon EBH treatment
(Fig. 3B). This effect was not due to EBH inhibition of phospho-
lipase activity, since vesicles incubated with EBH after formation
show as much phospholipase activity as untreated vesicles (data
not shown). The reduction in activity could not be explained by
effects of the epoxide on permeability of the vesicle, since permea-
bilizing the OMVs did not alter vesicle phospholipase activity (see
Fig. S3A in the supplemental material). We also tested culture
supernatants to measure phospholipase activity in toto and found
that there was less activity (see Fig. S3B). qRT-PCR analysis of the
FIG 2 Other epoxides affect Cif packaging. Effects of 3-bromo-1,2-propane-
diol (3Br) (an EBH hydrolysis product), styrene oxide (SO), glycidol (Gly),
and epoxyhexane (EH) on Cif packaging into vesicles was assessed byWestern
blotting. Chemical structures are depicted at the top. Levels of Cif under the
glycidol- and EH-treated conditions are less robust than those observed for the
EBH-treated cells; however, the levels of Cif in glycidol- and EH-treated cells
are higher than that of OMVs isolated from untreated bacterial cultures.
FIG 3 Epoxides alter virulence factor activity of OMVs. (A) Alkaline phos-
phatase activity associated with OMVs from EBH-treated and untreated bac-
terial cells. OMVswere normalized by protein concentration, and fluorescence
of the 4-methylumbelliferyl phosphate cleavage product was measured over 2
h to evaluate phosphatase activity. No statistical difference between untreated
and EBH-treated samples was identified at any time point (P  0.05). Error
bars indicate SEM (n 3). (B) Analysis of phospholipase activity of protein-
normalized OMVs from untreated and EBH-treated bacterial cells, as mea-
sured by colorimetric detection of NPPC cleavage. Error bars indicate SEM
(n 3).
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phospholipases that contribute to this activity indicated no signif-
icant decrease in transcript abundance at 12 h (see Fig. S3C).
These data show that unlike the case with Cif and OprF, whose
levels in OMVs are increased after epoxide treatment, phospho-
lipase activity decreased. In contrast, not all virulence factors are
affected by epoxide treatment, since alkaline phosphatase activity
is unchanged inOMVswhen cells are treatedwith EBH. Thus, our
findings indicate a degree of specificity in response to epoxide
treatment, a point addressed in more detail below.
EBH does not induce hypervesiculation. Treatment of bacte-
rial cells with compounds such as antibiotics, as well as physio-
chemical stressors, induces hypervesiculation (7). Other groups
have tested whether various treatments or mutations alter vesicu-
lation by measuring membrane lipids and protein content of pu-
rified vesicles (11, 39). We tested whether epoxides cause hyper-
vesiculation using these reported methods. The protein and
membrane lipid levels of the vesicles from EBH-treated cultures
were not significantly different from those of untreated cultures
(Fig. 4A and B). These data suggest that P. aeruginosa does not
increase vesicle production in the presence of epoxides.
Vesicle shape and density are altered by EBH. Previous stud-
ies with P. aeruginosaOMVs have found that amajority of vesicles
migrate to a specific fraction of a density gradient during purifi-
cation (6, 20). After performing the same gradient purification, we
observed a difference in the migration pattern of the OMVs from
EBH-treated bacteria from that of the untreated control (Fig. 5A).
We observe a predominant single band of OMV in the strain
grown without EBH (Fig. 5A). For OMV from EBH-grown cells,
while some vesicles appeared to fall within the same density region
as the untreated vesicles, a second band, corresponding to a higher
density, was also observed when cells were treated with EBH. In-
terestingly, these vesicle density changes occurred only in re-
sponse to specific epoxides, since glycidol did not alter vesicle
density (see Fig. S4 in the supplemental material).
Given the striking changes in density, we suspected that
there might also be changes in vesicle morphology. We ob-
served vesicle morphology by TEM following extraction of
matched fractions from gradients of treated and untreated ves-
icles. The vesicles from untreated cultures from fraction 1 were
rather small, with little variation in size (Fig. 5B and 6). There
were vesicles present in the untreated culture from the second
fraction, although fewer and more variable in size, with a
smaller average size (Fig. 5C and 6).
Vesicles from the EBH-treated condition had a wider range of
sizes in the first fraction and greater irregularity in shape (Fig. 5D
and 6). The second fraction from EBH-treated samples contained
many more vesicles than the same fraction of the untreated vesi-
cles, although these vesicles were quite variable in size and many
were smaller than those observed in the first fraction (Fig. 5E and
6). Taken together, these data show that there are gross changes in
the morphology of vesicles produced in the presence of EBH.
EBH-treated vesicle fractions differ in protein profiles.After
identifying two vesicle populations for the EBH condition, we
speculated that there might be some differences in the protein
profiles of the vesicles in each fraction. We analyzed total vesicles
from the two fractions described above by Western blotting to
assess the amounts of Cif andOprF in each sample using an equiv-
alent amount of loaded protein (Fig. 7A).
Cif was detectable in both EBH fractions butmore abundant in
the first fraction. Likewise, for both the untreated and treated
vesicles, OprF was more abundant in the first fraction than the
second, although much more Cif and OprF was present in both
EBH fractions than in the untreated control.
Taking this analysis a step further, we analyzed the protein
profiles of these fractions by silver staining (Fig. 7B). Initial in-
spection of the silver-stained gels revealed a number of apparent
differences in both the proteins present in each sample and the
abundances of particular bands between the EBH-treated and un-
treated OMVs. We excised several of the bands showing differ-
ences between the samples and analyzed the bands by mass spec-
trometry (Fig. 7; see also Fig. S5 and Table S2 in the supplemental
material).
The highly abundant band in untreated fraction 1, near 50 kDa,
was identified as the aminopeptidase PepB (PaAP) (40), which is
greatly diminished in the same fraction of the vesicles from EBH-
treated cells. OprF, the next protein identified, at 37 kDa, is
much more apparent in both of the EBH fractions than in the
untreated fractions, verifying the Western blot data described
above. A band just below OprF in untreated fraction 1 corre-
sponded to the phospholipase PlcB. A prevalent band near 25 kDa
was identified as an N-acetyl-anhydromuramyl-L-alanine ami-
dase (N-AA-L-AA), a member of a protein family that is com-
monly involved in cell envelope biogenesis (41, 42). Although we
did not confirm the identification of these proteins by a second
method, these data support the conclusion that the proteins pres-
ent in vesicles grown in the presence of EBH differ from those
grown in its absence.
Epoxide response differs from known stress responses im-
pactingOMVproduction.Recently, multiple groups have shown
that stress can dramatically alter vesicle formation in P. aeruginosa
(15, 43, 44). We suspected that epoxides, which can be quite reac-
tive, might be generating a stress response that could alter vesicle
production in a manner similar to that with these previously de-
FIG 4 Total protein content and membrane lipids in OMVs are not affected
by EBH. (A) BCA measurement of total protein from OMVs isolated from 12
h cultures of P. aeruginosa grown in the absence (untreated) or presence of 1
mM EBH. (B) FM 4-64 quantification of the same OMV preparations as in
panel A. Error bars indicate SD (n 3).
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scribed stressors. We characterized gene expression in a few com-
mon stress response pathways to test this possibility.
We examined expression of lexA as a marker of SOS response
(43) in response to growth in epoxides and found no difference in
expression (Fig. 8A). The sodM and katA transcripts were used as
indicators of oxidative stress. These transcripts had levels of ex-
pression in the 1 mM EBH-treated cells similar to those in un-
treated cells. Finally, algD expression was measured as an indica-
tor of AlgU-mediated membrane stress response (15, 39). The
expression of this transcript was not significantly induced under
EBH conditions. Together these data indicate that epoxide-medi-
ated vesicle alteration does not act through the previously identi-
fied stress pathways.
Non-epoxide-mediated changes in vesicle cargo. To further
test whether any other signals could alter vesicle packaging in a
manner similar to that of epoxides, we purified vesicles from cul-
tures grown with subinhibitory concentrations of EBH, gentami-
cin, D-cycloserine, polymyxin B, cumene hydroperoxide, and
plumbagin and assessed changes in vesicle proteins as well as the
Cif protein. As can be seen in Fig. 8B, each of the stresses resulted
in a unique protein profile as determined by silver staining.
Western blot analysis of Cif abundance showed that treatments
targeted at protein synthesis (gentamicin), the cell wall (D-cyclos-
erine), and the cell membrane (polymyxin B) increased Cif pack-
aging relative to results for the untreated control, although not
nearly to the levels observed for cells treated with EBH (Fig. 8C).
Vesicles formed in the presence of oxidative stress-inducing com-
pounds, including cumene hydroperoxide and plumbagin,
showed decreased Cif packaging. These data further support our
hypothesis that alterations in Cif packaging are strongly specific to
the environmental signal to which the bacteria are exposed.
Proteomic analysis of P. aeruginosa OMVs and transposon
mutant screen to identify proteins that alter vesicle packaging.
We next attempted to identify factors that may contribute to the
altered packaging observed with EBH. First, we performed a pro-
teomic analysis of OMVs derived from P. aeruginosa PA14, as well
as two clinical isolates. A total of 443 proteins were identified in
OMVs, with diverse predicted protein localization (see Table S3
and Fig. S6 in the supplemental material). The proteins identified
aligned well with OMV proteins found in previous studies in P.
aeruginosa PA14 and PAO1 (19, 43, 45).
Using the proteomics data as a guide, we selected 150 pro-
teins either identified inmultiple samples or localized to the outer
membrane or periplasmic fractions for further analysis. Strains
carrying transposon mutations in the genes that coded for these
proteins were selected from the previously reported P. aeruginosa
PA14 mutant library (32), and OMVs from these mutants were
isolated. OMVs isolated from the transposon mutants were com-
pared toOMVs from the wild-type strain for both virulence factor
(phospholipase, phosphatase, and Cif) and outer membrane pro-
tein (OprF and Opr86) abundance (see Table S4 in the supple-
FIG 5 EBH alters OMV shape and density. (A) Image of density gradients
after 20 h of centrifugation. The majority of vesicles from untreated cultures
fall within a distinct band (left), whereas theOMVs isolated fromEBH-treated
bacteria migrate in two distinct bands (right). Boxes indicate fractions sam-
pled. (B) TEM of negatively stained vesicles from fraction 1 of untreated bac-
teria. (C) Vesicles from fraction 2 of untreated bacteria. (D) Vesicles from
OMV fraction 1 of EBH-treated bacteria. (E) Vesicles fromOMV fraction 2 of
EBH-treated bacteria. Note the variability in vesicle size in panels D and E.
Scale bar, 100 nm.
FIG 6 Quantifying OMV size in each gradient fraction. Box-and-whisker plot
shows estimated area of vesicles (measured as pixels/OMV). The light-gray line
denotes themean.Note that the vertical axis is on a log scale. The differences in
average vesicle size between OMVs from fractions 1 and 2 of untreated cells
and between fractions 1 and 2 of EBH-treated cells is statistically significant (,
P 0.0001). Error bars indicate SD.
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mental material). Most of the mutations had little or no effect on
the factors tested. However, several mutations, most notably
mucD::TnM, folE2::TnM, and ppsA::TnM, did impact the packag-
ing of several proteins. Unfortunately, none of the mutants fit the
profile of the EBH-treated OMVs. Nonetheless, these data do
show that the loss of certain proteins identified in P. aeruginosa
OMVs can impact proper sorting of proteins into OMVs.
OMVs fromEBH-grownP. aeruginosa are less cytotoxic and
elicit an altered cytokine response.We had observed differences
in the virulence factors identified in OMVs produced by bacteria
grownwith EBH, but the functional consequences of such changes
in regard to host-pathogen interactions were not clear.
To assess the consequences of changing OMV cargo, we ap-
plied purified vesicles, isolated frombacteria grown in the absence
and presence of EBH, to a monolayer of immortalized airway
epithelial cells andmeasured lactate dehydrogenase (LDH) release
as an indicator of cytotoxicity to host cells (Fig. 9A). After 12 h,
OMVs fromEBH-treated bacteria had no effect on LDHrelease by
airway epithelial cells compared to results for vehicle (PBS) con-
trols, indicating that OMVs isolated from EBH-treated P. aerugi-
nosa PA14 cause little damage to the host cells. However, OMVs
from untreated bacterial cultures were highly cytotoxic. Similar
results were obtained after 24 h, where the average LDH release
fromOMVs produced by bacterial cells without EBH was close to
80%. In contrast, LDH released by airway cells treated withOMVs
from EBH-grown bacteria was not significantly different from
that for the untreated control epithelial cells (P 0.089).
FIG 7 Protein composition is different in OMV fractions. (A) Western blots
of vesicle fractions. Cif is abundant in both fractions from EBH-treated cells
(top). OprF is present in all fractions with the highest concentration in the
OMVs fromEBH-treated cells (bottom). (B) Silver-stained polyacrylamide gel
of the OMVs fractions indicated at the top of panel B. Note the differences in
proteins in each fraction. The predicted identities of proteins based on band
excision and analysis via mass spectroscopy are indicated by arrows. Note: in
some instances, protein concentrations were high enough to exclude the silver
stain, and these bands appear as dark regions with light centers, as can be seen
with the aminopeptidase band in fraction 1 from untreated cells and the band
marked N-acetyl-anhydromuramyl-L-alanine amidase (N-AA-L-AA) in frac-
tion 1 of EBH-treated vesicles. See Fig. S5 and Table S2 in the supplemental
material for a complete description of proteins identified.
FIG 8 Epoxides do not activate typical stress response pathways. (A) EBH
does not increase expression of typical stress response genes. qPCR analysis of
four pathways involved in response to DNA damage (lexA) and oxidative
(sodM and katA) and membrane stress (algD) in P. aeruginosa grown in the
presence or absence of EBH is shown. Error bars indicate SD (n  3). (B)
Silver-stained gel of OMVs harvested from bacteria grown in the presence of
subinhibitory concentrations of EBH, gentamicin, D-cycloserine, polymyxin
B, cumene hydroperoxide, and plumbagin (20 g total protein per well). Mo-
lecular weight size markers are indicated on the left. (C) Western blot of Cif
protein levels of OMVs isolated from cifR mutant bacteria grown in the
presence of the above stressors. The lane labels correspond to those shown in
panel B.
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The dramatic differences in cytotoxicities of theOMVs isolated
from untreated and EBH-treated P. aeruginosa PA14 suggested
that there may be differences in the immune responses to the two
populations of vesicles; thus, we examined expression of four cy-
tokines previously shown to be induced by P. aeruginosa (46).
After 24 h of incubation with OMVs, large differences were ob-
served in cytokine production in airway epithelial cells exposed to
OMVs from EBH-grown bacteria versus vesicles from control
bacteria (grown in the absence of EBH). IL-8, Gro	 (CXCL1), and
Gro
 (CXCL2) were decreased roughly 5- to 25-fold in the airway
epithelial cells exposed to OMVs from EBH-treated bacteria com-
pared to results with OMVs grown in the absence of EBH (Fig.
9B). Interestingly, the opposite response was observed for IL-6
expression, which was higher in airway epithelial cells treated with
OMVs from EBH-grown bacteria than in those treated with con-
trol OMVs.
The data presented here show that the alterations in OMVs
grown in the presence versus the absence of EBH result in strong
effects on airway epithelial cell cytotoxicity of, and immune re-
sponse to, these vesicles and thus result in functional conse-
quences for the host-pathogen interaction.
DISCUSSION
Over the past 20 years, a number of factors that alter vesiculation
in some way, including antibiotics, antimicrobial peptides, and
quorum-sensing molecules, have been identified (12, 14, 18).
Here, we describe the first link of a specific virulence factor in-
ducer, epoxides, to alteration in the virulence factor’s packaging
into OMVs.
We had previously shown that Cif was packaged into OMVs
and OMV-mediated Cif delivery was a highly effective means of
transporting this virulence factor into airway epithelial cells (6,
21).We believe the abundance of Cif in OMVs is a physiologically
relevant question, since Cif efficacy in impacting host cell biology
is 17,000 times greater when delivered by OMVs than with appli-
cation of the pure protein (6). Here, we tested the ability of EBH,
a strong inducer of cif gene expression and a model epoxide (25),
to affect packaging of this virulence factor into OMVs. Indeed, in
the wild-type strain, the Cif protein was increased in the sphero-
plast and periplasm fractions and in OMVs (Fig. 1A). Surpris-
ingly, deletion of the cifR gene, coding for the repressor of cif gene
expression, had a dramatic effect on Cif expression, boosting Cif
levels in the spheroplast and periplasm by 5-fold, but this in-
crease in cell-associated Cif had only a modest effect on Cif pack-
aging. In contrast, growth of the cifR mutant in the presence of
EBH resulted in a large boost in Cif packaging into OMVs (Fig.
1A). These data support previous suggestions of selective packag-
ing of OMVs (47–49).
In prior studies, we had also characterized Cif production in
the presence of a suite of different epoxides and found that there
was selectivity of inducers (26). Here, we sought to test whether
there was similar selectivity for the packaging response. We se-
lected a strong inducer of cif gene expression, styrene oxide, and
two poor inducers, glycidol and epoxyhexane, as well as the vicinal
diol of EBH (which does not induce cif gene expression), as a
control for epoxide hydrolysis products contributing to this phe-
notype. The Cif packaging data trended very closely with the ex-
pression data reported previously, and while glycidol is structur-
ally quite similar to EBH (a hydroxyl substituted for a bromine), it
had only a limited effect on vesicle packaging (Fig. 2). Note that
these studies are performed in a strain lacking the CifR repressor,
so the changes in Cif packing are independent of this regulator.
In addition to the changes in Cif, we observed that changes in
other vesicle cargo, OprF (Fig. 1B) and a putative envelope bio-
genesis protein (Fig. 7B), increased in OMVs isolated from bacte-
ria grown with EBH. At this point, we do not understand the
mechanism(s) underlying the differential packaging of proteins
observed in bacteria grown with EBH. For example, the differ-
ences in protein complement in OMVs may reflect changes in
membrane composition of theOMVs as a result of EBH treatment
or be a secondary consequence of the change in OMV shape and
size for EBH-treated cells. It is also possible that the changes in
OMV morphology are a consequence of the different proteins
they carry.
We considered the possibility thatOMVshave specific proteins
that recruit cargo into the OMV, analogous to protein trafficking
pathways in eukaryotic cells (50). To identify such factors, we
performed proteomic analysis of OMVs and screened the OMVs
FIG 9 OMVs from EBH-treated cells are less cytotoxic and elicit an altered
immune response. (A) Cytotoxicity of OMVs applied to airway epithelial cells.
Cytotoxicity is measured as percent LDH released from epithelial cells relative
to results for a lysis control (100%LDH release) for epithelial cells treated with
OMVs from control cultures (OMV, -EBH), OMVs from bacteria grown with
EBH (OMV,EBH), or the vehicle control (Untreated). “” indicates statis-
tically significantly different (P  0.05) from the “untreated” condition; ns,
not significant (P 0.05). (B) Cytokine production of epithelial cells treated
for 24 h with OMVs. ELISAs were performed for IL-8, IL-6, Gro	, and Gro
.
Note that cytokinemeasurements are on a log scale. “” indicates a statistically
significant difference (P 0.05) when comparing treatment with OMVs from
control cultures (OMV, -EBH) to the vehicle control (Untreated). “” indi-
cates a statistically significant difference (P 0.05)when comparing treatment
with OMVs from EBH-grown cultures (OMV,EBH) to the vehicle control
(Untreated). The legend in panel A also corresponds to the bars in panel B. For
both panels, error bars indicate SD (n 3).
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derived from 150 strains lacking OMV-associated proteins
identified by mass spectroscopy. Unfortunately, none of these
mutants showed alterations of protein cargo specific to epoxide-
treated OMVs (see Table S4 in the supplemental material). De-
spite the lack of epoxide-related alterations in packaging, many
mutations did alter the screened vesicle cargo. This finding sug-
gests that protein interactions may play a role in vesicle protein
sorting, although more study is required to address this point.
Importantly, the fluctuation in virulence factor cargo in the
EBH OMVs suggested that there might be functional differences
in the OMVs from EBH-grown bacteria. We examined OMV-
induced cytotoxicity on airway epithelial cells and found that EBH
treatment reduced cytotoxicity of OMVs. EBH treatment con-
trasts sharply with ciprofloxacin treatment, which has been shown
to increase OMV cytotoxicity in P. aeruginosa (45). Moreover,
IL-8, Gro	, and Gro
 have been shown to be important for neu-
trophil recruitment and P. aeruginosa clearance (51, 52). The dra-
matic reduction seen in these cytokines in response to the OMVs
from EBH-grown cultures, compared to results with OMVs iso-
lated from vehicle-treated cultures, could indicate changes in the
abundance or nature of the pathogen-associated molecular pat-
terns (PAMPs) (such as LPS or flagellin). IL-6 is a chemokine with
pleiotropic effects, acting as both a proinflammatory and anti-
inflammatory cytokine (53). The increase in IL-6 expression seen
with the EBH treatment vesicles relative to that with the untreated
vesicles is interesting, since it could indicate that these vesiclesmay
actively limit inflammation or at the very least alter the immune
response to P. aeruginosa. Thus, the changes in the OMV comple-
ment in the presence of epoxides appear to have a functional con-
sequence in regard to host-pathogen interactions. It is tempting to
infer from these data that when P. aeruginosa encounters epox-
ides, as it may in the lung, this microbe modulates its OMV cargo
to be less cytotoxic and immunogenic as part of its adaptation to a
chronic lifestyle.
In summary, it is clear that a variety of environmental factors
impact the suite of proteins found in OMVs. And while themech-
anism that leads to these differences in OMV content are unclear,
modulating the protein content in response to environmental
cues could have important implications regarding howOMVs im-
pact host cell function and immune response.
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